 Cystic Fibrosis Transmembrane Conductance Regulator
"Cystic Fibrosis Transmembrane Conductance Regulator" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chloride channel that regulates secretion in many exocrine tissues. Abnormalities in the CFTR gene have been shown to cause cystic fibrosis. (Hum Genet 1994;93(4):364-8)
| Descriptor ID |
D019005
|
| MeSH Number(s) |
D12.776.157.530.100.304.500 D12.776.157.530.400.175.125 D12.776.157.530.450.074.500.500.500.500 D12.776.543.550.450.175.125 D12.776.543.585.100.304.500 D12.776.543.585.400.175.125 D12.776.543.585.450.074.500.500.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cystic Fibrosis Transmembrane Conductance Regulator".
Below are MeSH descriptors whose meaning is more specific than "Cystic Fibrosis Transmembrane Conductance Regulator".
This graph shows the total number of publications written about "Cystic Fibrosis Transmembrane Conductance Regulator" by people in this website by year, and whether "Cystic Fibrosis Transmembrane Conductance Regulator" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 1 | 1 | 2 | | 2002 | 4 | 1 | 5 | | 2003 | 1 | 2 | 3 | | 2004 | 5 | 4 | 9 | | 2005 | 1 | 2 | 3 | | 2006 | 4 | 3 | 7 | | 2007 | 5 | 3 | 8 | | 2008 | 3 | 4 | 7 | | 2009 | 8 | 2 | 10 | | 2010 | 4 | 1 | 5 | | 2011 | 3 | 3 | 6 | | 2012 | 2 | 1 | 3 | | 2013 | 4 | 0 | 4 | | 2014 | 6 | 2 | 8 | | 2015 | 7 | 2 | 9 | | 2016 | 4 | 7 | 11 | | 2017 | 3 | 3 | 6 | | 2018 | 4 | 1 | 5 | | 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cystic Fibrosis Transmembrane Conductance Regulator" by people in Profiles.
-
Chioccioli M, Feriani L, Kotar J, Bratcher PE, Cicuta P. Phenotyping ciliary dynamics and coordination in response to CFTR-modulators in Cystic Fibrosis respiratory epithelial cells. Nat Commun. 2019 04 16; 10(1):1763.
-
Pohl K, Nichols DP, Taylor-Cousar JL, Saavedra MT, Strand MJ, Nick JA, Bratcher PE. Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation. PLoS One. 2018; 13(12):e0209026.
-
Holguin F. Triple CFTR Modulator Therapy for Cystic Fibrosis. N Engl J Med. 2018 10 25; 379(17):1671-1672.
-
Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 10 25; 379(17):1599-1611.
-
Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 10 25; 379(17):1612-1620.
-
Modena BD. Genetic Variants and Altered Expression of Non-CFTR Genes May Explain Differences in Cystic Fibrosis Severity. Am J Respir Crit Care Med. 2018 01 01; 197(1):7-9.
-
Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, Wang LT, Ingenito EP, McKee C, Lu Y, Lekstrom-Himes J, Elborn JS. Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med. 2017 11 23; 377(21):2013-2023.
-
Pittman JE, Noah H, Calloway HE, Davis SD, Leigh MW, Drumm M, Sagel SD, Accurso FJ, Knowles MR, Sontag MK. Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginosa infection. PLoS One. 2017; 12(5):e0177215.
-
Hoppe JE, Zemanick ET. Lessons from the lower airway microbiome in early CF. Thorax. 2017 12; 72(12):1063-1064.
-
Donaldson SH, Solomon GM, Zeitlin PL, Flume PA, Casey A, McCoy K, Zemanick ET, Mandagere A, Troha JM, Shoemaker SA, Chmiel JF, Taylor-Cousar JL. Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR. J Cyst Fibros. 2017 May; 16(3):371-379.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|